Year: 2019

Henning Beltestad, konsernleder i Lerøy Seafood Group ASA (LSG), har den 19. november 2019 kjøpt 20.000 aksjer i LSG til en gjennomsnittskurs på 54,68 per aksje. Beholdningen etter denne transaksjonen er 20.000 aksjer i LSG.Annichen Edvardsen, finanssjef i Lerøy Seafood Group ASA (LSG), har den 19. november 2019 kjøpt 1.000 aksjer i LSG til en gjennomsnittskurs på 54,00 per aksje. Beholdningen etter denne transaksjonen er 2.200 aksjer i LSG.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Steel Valley Brew Works to offer local brews – both craft beer and specialty coffeeLocal business owner shares Youngstown pride and excitement for area’s futureAnnouncement of neighbors to Steel Valley Brew Works to follow in near future, which include an indoor golf entertainment center, additional entertainment and dining offeringsDemolition of former Sears location remains on pace, to be replaced by DeBartolo Commons, a new four-acre athletic and entertainment green space and event venueCOLUMBUS, Ohio, Nov. 19, 2019 (GLOBE NEWSWIRE) — Washington Prime Group Inc. (NYSE: WPG) today announced that Steel Valley Brew Works, a new, local brew and entertainment venue, will be one of several entertainment concepts to anchor redevelopment efforts at Southern Park Mall.Steel Valley Brew Works will overlook and connect to DeBartolo Commons,...

VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce the appointment of Dr. David Ostrow, MD as Chief Medical Officer. Additionally,  Mona Elesseily will be joining the newly formed advisory board as a Digital Marketing Strategist.Dr. Ostrow brings a wealth of knowledge and operational experience within healthcare and in this role will help forge alliances to form a meaningful and operational liaison between Premier Health and local health authorities. Mona provides keen digital marketing strength and brings vast experience improving marketing campaigns...

NEW YORK and TORONTO, Nov. 19, 2019 (GLOBE NEWSWIRE) — NexTech AR Solutions (the “Company” or “NexTech”) (OTCQB:NEXCF) (CSE:NTAR) (FSE:N29), the industry leader in augmented reality, is pleased to announce it has partnered with LivePerson (NASDAQ:LPSN), a global leader in conversational commerce solutions, to integrate augmented reality (AR) for enhanced product views and 3D advertising into LivePerson’s AI-powered conversational commerce platform.The partnership offers powerful new retail capabilities for showcasing products and shopping on messaging channels, including SMS, Facebook Messenger, WhatsApp, RCS, and Apple Business Chat. This one-of-a-kind, transformative technology gives retailers the power to convert shoppers into buyers, reduce returns, and build brand loyalty by measuring customer responses to products in real-time.Click...

BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the European Medicines Agency (EMA) has granted access to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who are not adequately responding to a C5 inhibitor. The decision from the EMA was based on danicopan safety and efficacy data from the Phase 2 PNH combination trial. The top-line 24-week results from this combination trial was accepted for poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting scheduled for December 9th in Orlando,...

GAITHERSBURG, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) announced today that the Center for Disease Control (CDC) has released updated data increasing the number of deaths in the United States (U.S.) from antibiotic-resistant bacteria and fungi, and highlighting the continuing threat of rising antibiotic resistance. According to the CDC, these pathogens cause more than 2.8 million infections and 35,000 deaths in the U.S. each year. That means, on average, someone in the United States gets an antibiotic-resistant infection every 11 seconds, and every 15 minutes, someone dies1.  OpGen’s products have been developed to help combat these growing threats. The Acuitas® AMR Gene Panel test, currently in development, is designed to help identify drug-resistant pathogens directly from urine as an aid in the diagnosis...

DALLAS, Nov. 19, 2019 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced two new industrial awards with a combined value over $30 million. The contracts were secured by Primoris Industrial Constructors, part of the Power, Industrial, & Engineering segment.Both projects are located in the southern United States for a major industrial customer and consist mainly of civil and underground piping work for new syngas units.Primoris Fabrication and Primoris I&M will perform work on the projects as subcontractors to Primoris Industrial Constructors.Work is scheduled to commence in the fourth quarter of 2019, and completion is expected in the third quarter of 2020.ABOUT PRIMORISFounded in 1960, Primoris, through various subsidiaries, has grown to become one of...

Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeksAchieved all six key secondary endpoints, including superiority to leuprolide acetate on rapid suppression of testosterone and prostate-specific antigen (PSA), all with p-values < 0.0001New Drug Application (NDA) submission expected in the second quarter of 2020Conference call and webcast to be held today at 8:30 a.m. EST / 5:30 a.m. PSTBASEL, Switzerland, Nov. 19, 2019 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with...

FOR IMMEDIATE RELEASE

TORONTO, Nov. 19, 2019 (GLOBE NEWSWIRE) — The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) is pleased to announce that it has closed its previously announced credit facility from a syndicate of lenders led by ATB Financial (“ATB”) and including Farm Credit Canada. The $25 million facilities consist of a $24.5 million recapitalization term facility and a $500,000 revolving operating credit facility (together the “ATB Credit Facilities”). Pursuant to conditions of the ATB Credit Facilities, Flowr will receive a first tranche of funding of approximately $20.05 million on closing with the remaining of the recapitalization term facility available subject to certain conditions.“We are extremely pleased to strengthen our financial position through non-dilutive financing at attractive pricing,” commented Vinay Tolia,...